Exelixis wins Federal Circuit ruling upholding Cabometyx crystalline salt patents
EXEL•Federal Circuit upholds key Cabometyx patents
Exelixis won a Federal Circuit appeal that upheld validity of three cabozantinib crystalline malate salt patents, supporting CABOMETYX exclusivity.
The court dismissed as moot the appeal over a low-impurity cabozantinib formulation patent, leaving the broader patent estate intact.
Generic timing remains tied to further litigation
Earliest potential U.S. generic launch by MSN is January 15, 2030, subject to further appeals or regulatory exclusivity.
Generic timing also hinges on separate litigation over another low-impurity formulation patent expiring February 2032; trial set for November 2026.
